Member Info for CHELSEA7

90k

First Trade NEX

2/01/2019 08:00 9,054 8.99

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/SCLP/13940473.html

https://uk.linkedin.com/in/samantha-paston-b1310757

From yesterdays highlights, for those who didn"t see it........................................

Price: 8.80
Just Seen This!!Mon 21:35Prettysure someone has posted this, but for the nightbirds..........................

Samantha Paston has ended her long association with Immunocore to take up the head of research position at Scancell. Paston’s appointment is part of a broader effort by Scancell to add experience as it steps up its immunotherapy development activities.

Scancell is developing anticancer candidates based on two immunotherapy platforms, ImmunoBody and Moditope. The pipeline of ImmunoBody vaccines, led by clinical-phase NY-ESO-1 asset SCIB1, has advanced furthest, but the other platform has attracted attention and a T-cell receptor (TCR) deal with BioNTech.

With Scancell gearing up for trials and stepping up its TCR activities, the British biotech has added Paston to its team. Paston joined Avidex, the company that became Immunocore via an acquisition and spinout, straight after earning her doctorate in 2006 and stayed on throughout the early changes and more recent upheavals.

INDUSTRY RESEARCH
Veeva 2019 Unified Clinical Operations Survey
Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.
COMPLETE THE SURVEY
The upshot is that Paston has worked at Immunocore since it was founded in 2008. Having started out as a senior research scientist, Paston went on to lead the T cell cloning and cell biology groups during her 11 years at the TCR specialist. Paston will now apply this experience to the emerging range of R&D tasks facing Scancell.

"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics,” Lindy Durrant, Scancell’s founder and chief scientific officer, said in a statement. Paston will report directly to Durrant.

Scancell revealed news of Paston’s appointment alongside details of its new head of manufacturing. Adrian Parry, formerly head of small molecule CMC at Mereo BioPharma, has taken up the post, giving Scancell an employee with experience managing outsourced GMP production of clinical trial materials at a time when its manufacturing needs are growing.

"How very exciting!!!"

Must have been the first time in ages I was so tired, but excited too about Scancell. Scancell won by a mile,

So IMO two great appointments yesterday, some good press and hours away from GC Results. Yesterdays appointments just show how far we have come to lead such an experienced team, make appointments from our peer competitors and the article in Fierce Biotech gave rise for investors to see Scancell in a very different light........I hope.

So there was 2.2m declared traded yesterday, 70 trades including NEX, far from our normal 10!!! Lets see what the day has for us, with GC in mind too and good luck to us all as opportunity comes our way again.

Good posts today, and Ruck you are not on the naughty list at all, just offering alternative views which makes conclusionsnharder to call.

These are two serious appointments RNS ed today, just prior to GC results, they speak for themselves IMHO, and yes seek very positive to me, presuming a deal is at a pretty late stage now. As you said earlier a burgeoning pipeline is good but so are the demands for funding, makes sense to me. Have we ever been so close to a commercial deal???

Sorry, that was headline news in Fierce Biotech today.

Prettysure someone has posted this, but for the nightbirds..........................

Samantha Paston has ended her long association with Immunocore to take up the head of research position at Scancell. Paston’s appointment is part of a broader effort by Scancell to add experience as it steps up its immunotherapy development activities.

Scancell is developing anticancer candidates based on two immunotherapy platforms, ImmunoBody and Moditope. The pipeline of ImmunoBody vaccines, led by clinical-phase NY-ESO-1 asset SCIB1, has advanced furthest, but the other platform has attracted attention and a T-cell receptor (TCR) deal with BioNTech.

With Scancell gearing up for trials and stepping up its TCR activities, the British biotech has added Paston to its team. Paston joined Avidex, the company that became Immunocore via an acquisition and spinout, straight after earning her doctorate in 2006 and stayed on throughout the early changes and more recent upheavals.

INDUSTRY RESEARCH
Veeva 2019 Unified Clinical Operations Survey
Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.
COMPLETE THE SURVEY
The upshot is that Paston has worked at Immunocore since it was founded in 2008. Having started out as a senior research scientist, Paston went on to lead the T cell cloning and cell biology groups during her 11 years at the TCR specialist. Paston will now apply this experience to the emerging range of R&D tasks facing Scancell.

"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics,” Lindy Durrant, Scancell’s founder and chief scientific officer, said in a statement. Paston will report directly to Durrant.

Scancell revealed news of Paston’s appointment alongside details of its new head of manufacturing. Adrian Parry, formerly head of small molecule CMC at Mereo BioPharma, has taken up the post, giving Scancell an employee with experience managing outsourced GMP production of clinical trial materials at a time when its manufacturing needs are growing.

"How very exciting!!!"

Never thought i would see 9.10 on the ask and feel like celebrating!!!!!

Just got home, think it was 8.10/8.50 when i left, and no sign of our seller this afternoon at above 8.00p.

As I posted this morning, last two times we spiked at 17/18p we had a big line of shares being sold at 11/12p beforethe rise.

Exciting times, night guys

SCAP 8.10/8.50

Another coffee Ruck?

Still being paid, another 50k and 17k..........five times now. Catch yer later, UCLH calling.

Makes you wonder Ruck, but yes as excited as we can be about the pipeline, the funding issues increase, hence IMHO why we have been getting weaker in the market. Two very experienced scientists now with us. Something up??

As i said last week though, we saw heavy selling, for us, around 11/12p just prior to our spikes last year at 17/18p

Tend to agree Ruck. IF that is the reason for our weakness, it makes sense to me, but something tells me we are on the brink of funding news, even to employ two more scientists. Soon find out!!!!

Agreed.

As the volume rises above 1.4m

21/01/2019 10:07 4,000 8.47
21/01/2019 10:05 50,000 8.37
21/01/2019 09:56 50,000 8.417
21/01/2019 09:07 14,213 8.16
21/01/2019 08:58 20,000 8.16
21/01/2019 08:46 10,000 8.17
21/01/2019 08:39 30,105 8.03
21/01/2019 08:38 50,000 8.17

I noticed Immunacore appointed a new CEO last week, could be a very interesting Proactive this week